Stockreport

PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency

PHASERX  (PZRX) 
US:NASDAQ Investor Relations: investor.phaserx.com/investors/default.aspx
PDF SEATTLE, April 25, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver disease [Read more]